- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00000274
Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9
January 11, 2017 updated by: National Institute on Drug Abuse (NIDA)
Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics
The purpose of this study is to evaluate the safety and efficacy of flupenthixol and haloperidol for cocaine dependence in individuals with schizophrenia/schizoaffective illness.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment
60
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- New York State Psychiatric Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Please contact site for information.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Drug use
|
Side effects
|
Cocaine craving
|
Psychiatric symptoms
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 1997
Study Completion
May 1, 1999
Study Registration Dates
First Submitted
September 20, 1999
First Submitted That Met QC Criteria
September 20, 1999
First Posted (Estimate)
September 21, 1999
Study Record Updates
Last Update Posted (Estimate)
January 12, 2017
Last Update Submitted That Met QC Criteria
January 11, 2017
Last Verified
November 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Pathologic Processes
- Substance-Related Disorders
- Disease
- Cocaine-Related Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Dopamine Agents
- Dopamine Antagonists
- Flupenthixol
- Flupenthixol decanoate
Other Study ID Numbers
- NIDA-09236-9
- P50-09236-9
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Substance-Related Disorders
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA)CompletedSubstance-Related Disorders | Substance Use | Substance Use Disorders | Substance Abuse | Substance Dependence | Substance Related Problem
-
VA Office of Research and DevelopmentRecruiting
-
National Institute on Drug Abuse (NIDA)CompletedSubstance-related Disorders
-
US Department of Veterans AffairsCompletedAlcoholism | Substance Use Disorders | Substance Abuse | Alcohol Abuse | Substance DependenceUnited States
-
Norwegian University of Science and TechnologyCompletedSubstance-related DisordersNorway
-
University of Southern CaliforniaNational Institute on Drug Abuse (NIDA)Completed
-
University Hospital, Basel, SwitzerlandPsychiatric Hospital of the University of BaselCompleted
-
University of LuebeckFederal Ministry of Health, GermanyCompletedSubstance-related Disorders
-
University of Illinois at Urbana-ChampaignCompletedSubstance-related Disorders
-
University of NebraskaCompletedSubstance-related Disorders | Alcohol-related DisordersUnited States
Clinical Trials on Flupenthixol
-
National Institute on Drug Abuse (NIDA)New York State Psychiatric InstituteCompleted
-
National Institute on Drug Abuse (NIDA)Unknown
-
Peking University Third HospitalCompletedEmotional Disorder | Neurologic DisorderChina
-
National Institute on Drug Abuse (NIDA)New York State Psychiatric InstituteCompleted
-
National Institute on Drug Abuse (NIDA)Friends Research Institute, Inc.Completed
-
H. Lundbeck A/SCompleted
-
H. Lundbeck A/SCompletedHealthy Men and WomenUnited Kingdom
-
Taichung Veterans General HospitalCompletedCentral Nervous System Diseases | Metabolic Syndrome | Schizophrenia; Psychosis | Antipsychotic Agents | Olanzapine | Flupentixol | Clinical Therapy | QuetiapineTaiwan
-
Mahidol UniversityCompleted
-
RenJi HospitalRecruitingDyspepsia | Functional Gastrointestinal Disorders | Antidepressant Drug Adverse Reaction | Antidepressant Discontinuation SyndromeChina